Posts Tagged :

Clinical Outcomes

The Role of Health System Specialty Pharmacy in Cardiometabolic Disease Care 70 70 Shields Health Solutions

The Role of Health System Specialty Pharmacy in Cardiometabolic Disease Care

Unlock Better Outcomes in Cardiometabolic Disease Care Cardiometabolic disease (CMD) is one of the most pressing healthcare challenges of our time—driving trillions in costs and impacting millions of lives. From diabetes…

Ambulatory Clinical Pharmacist Impact on Coverage Outcomes for Specialty Oncology Medications 216 115 Shields Health Solutions

Ambulatory Clinical Pharmacist Impact on Coverage Outcomes for Specialty Oncology Medications

    This poster evaluates the cimpact of an ACP program on third party pharmacy coverage determination outcomes for specialty oncology medications prescribed from these clinics.  

Clinical, Safety, and Quality Outcomes of a Hypertrophic Cardiomyopathy Clinical Pharmacy Management Program 216 115 Shields Health Solutions

Clinical, Safety, and Quality Outcomes of a Hypertrophic Cardiomyopathy Clinical Pharmacy Management Program

    This poster evaluates the clinical, safety, and quality outcomes of a pharmacist-led HCM clinical management program.  

Analysis of Oral Oncolytic Waste for Patients Filling at a Health System Specialty Pharmacy 216 115 Shields Health Solutions

Analysis of Oral Oncolytic Waste for Patients Filling at a Health System Specialty Pharmacy

    This poster evaluates existing oral oncology medication waste events among patients filling at a HSSP.  

How CHRISTUS Health Reimagined Diabetes Support Through Health System Specialty Pharmacy 70 70 Shields Health Solutions

How CHRISTUS Health Reimagined Diabetes Support Through Health System Specialty Pharmacy

This white paper explores the opportunities and unknowns that health organizations must consider when weighing the implementation of AI.
Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacy 70 70 Shields Health Solutions

Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacy

  According to the CDC, approximately 38 million Americans have diabetes (about 1 in 10) and approximately 90-95% of those have type 2 diabetes. GLP-1 and GLP-1/GIP agonists are now recognized…

Shields Outcomes 2024 Report 70 70 Shields Health Solutions

Shields Outcomes 2024 Report

This white paper explores the opportunities and unknowns that health organizations must consider when weighing the implementation of AI.
Clinical and Quality Outcomes of a Bleeding Disorder Program in a Health System Specialty Pharmacy 216 115 Shields Health Solutions

Clinical and Quality Outcomes of a Bleeding Disorder Program in a Health System Specialty Pharmacy

This poster evaluates the clinical and quality outcomes of a bleeding disorder program at a health system HSSP.

Establishing Proportion of Days Covered Benchmarks for Health System Specialty Pharmacy Clinical Outcomes Evaluation 216 115 Shields Health Solutions

Establishing Proportion of Days Covered Benchmarks for Health System Specialty Pharmacy Clinical Outcomes Evaluation

This poster aims to establish goals for a dashboard displaying medication adherence by disease state and PDC thresholds through a comprehensive literature review, validating the existing targets.

Impact of an Integrated Health System Specialty Pharmacy on Clinical and Operational Outcomes in Cystic Fibrosis Patients 216 115 Shields Health Solutions

Impact of an Integrated Health System Specialty Pharmacy on Clinical and Operational Outcomes in Cystic Fibrosis Patients

This poster explores the impact of a Health System Specialty Pharmacy care model paired with a pharmacist-led CDTM program on CF patient outcomes.